Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 338

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 338
---
-inflammatory drug (“NSAID”) based therapeutics. These options suffer from sight-threatening complications such as Glaucoma and corneal melting, thus there is a large unmet need for other approaches. As an example of the potential patient population, Channel estimates that there are approximately 5 million cases of corneal abrasions per year in the United States. In addition, other potential indications associated with eye pain include:

| • | severe dry eye, |

| • | side effects from photorefractive keratectomy (PRK) and pterygium surgery, |

| • | second eye cataract surgery, |

| • | neuropathic corneal pain, and |

| • | severe uveitis and severe iritis/scleritis. |

As NaV1.7 channels are present on the cornea and is a viable biological target for treating eye pain, Channel believes that Channel has a sound scientific basis for Channel’s ability to treat a multitude of eye pain indications. Channel has successfully developed an eye drop formulation and have determined that the eye drops are well tolerated by animals. Channel has completed animal efficacy studies and are in the process of running toxicology studies on animals. Channel expects to announce the efficacy and toxicology results by April 2025. Following the animal studies, if successful, Channel intends to move into POC studies in humans. Channel plans to conduct the POC study in Australia to avail itself of a 43.5% tax credit for clinical expenses incurred in Australia and, on January 9, 2023, established an Australian subsidiary through which the work will be conducted. Channel is planning to conduct the POC in a clinic in Brisbane, Australia and are in the process of contracting the services to perform such trial.

188

#### TABLE OF CONTENTS
Depot Program : Based on several novel formulations of CC8464, Channel’s most recently launched program, titled CT3000, is for the potential treatment of post operative pain with the use of nerve blocks. Examples would include knee surgery or shoulder surgery. Existing therapies for nerve blocks lead to neuromuscular blockade which prevents movement following surgery. Doctors often want patients to move soon after surgery to avoid complications such as blood clots. A NaV1.7 inhibitor used for nerve blocks may provide good analgesia but will not lead to neuromuscular blockade that prevents movement like other local anesthetics.

Channel has successfully developed a number of formulations and in December 2024, announced that it achieved its